Literature DB >> 1458703

Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis.

F De Benedetti1, P Robbioni, M Massa, S Viola, S Albani, A Martini.   

Abstract

We measured serum and synovial fluid interleukin 6 (IL-6) levels in patients with polyarticular-onset and pauciarticular-onset juvenile chronic arthritis (JCA), using the hybridoma cell line B9. During active disease, but not during remission, serum IL-6 levels were significantly elevated in patients with polyarticular (p < 0.0001 vs controls) and in patients with pauciarticular JCA (p < 0.01 vs controls). In patients with active polyarticular disease (polyarticular and extended pauciarticular) serum IL-6 levels correlated with the extent and severity of joint involvement (p < 0.05), with erythrocyte sedimentation rate values (p < 0.005) and with C reactive protein concentrations (p < 0.05). In patients with persistent pauciarticular JCA, serum IL-6 levels correlated with the joint swelling score (p < 0.05). Synovial fluid IL-6 levels, measured in 5 patients with pauciarticular JCA, were markedly elevated (range 600-24,000 HGF U/ml). In conclusion, our data suggest that IL-6 is an important pathogenic mediator in polyarticular and pauciarticular JCA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1458703

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  21 in total

1.  Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation.

Authors:  F De Benedetti; T Alonzi; A Moretta; D Lazzaro; P Costa; V Poli; A Martini; G Ciliberto; E Fattori
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  Interleukin-1, -6, and -8 levels in juvenile chronic arthritis.

Authors:  S Ozen; U Saatci; A Bakkaloglu; O Ozdemir; N Besbas; S Kirazli; S Ozdemir
Journal:  Clin Rheumatol       Date:  1997-03       Impact factor: 2.980

3.  IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro.

Authors:  Shoichi Kaneshiro; Kosuke Ebina; Kenrin Shi; Chikahisa Higuchi; Makoto Hirao; Michio Okamoto; Kota Koizumi; Tokimitsu Morimoto; Hideki Yoshikawa; Jun Hashimoto
Journal:  J Bone Miner Metab       Date:  2014-07       Impact factor: 2.626

4.  Dilemmas of low dosage glucocorticoid treatment in rheumatoid arthritis: considerations of timing.

Authors:  A T Masi; G P Chrousos
Journal:  Ann Rheum Dis       Date:  1997-01       Impact factor: 19.103

5.  Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis.

Authors:  B A Eberhard; R M Laxer; U Andersson; E D Silverman
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

6.  Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.

Authors:  F De Benedetti; M Massa; P Pignatti; S Albani; D Novick; A Martini
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

7.  The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial.

Authors:  Sudha Visvanathan; Carrie Wagner; Joseph C Marini; Daniel J Lovell; Alberto Martini; Ross Petty; Ruben Cuttica; Patricia Woo; Graciela Espada; Marco Gattorno; Maria T Apaz; Eileen Baildam; Anders Fasth; Valeria Gerloni; Pekka Lahdenne; Pierre Quartier; Rotraud Saurenmann; Suzanne Travers; Alan Mendelsohn; Stephen Xu; Edward H Giannini; Nicolino Ruperto
Journal:  Pediatr Rheumatol Online J       Date:  2010-09-07       Impact factor: 3.054

8.  Immature cell populations and an erythropoiesis gene-expression signature in systemic juvenile idiopathic arthritis: implications for pathogenesis.

Authors:  Claas H Hinze; Ndate Fall; Sherry Thornton; Jun Q Mo; Bruce J Aronow; Gerlinde Layh-Schmitt; Thomas A Griffin; Susan D Thompson; Robert A Colbert; David N Glass; Michael G Barnes; Alexei A Grom
Journal:  Arthritis Res Ther       Date:  2010-06-24       Impact factor: 5.156

Review 9.  Tocilizumab in pediatric rheumatology: the clinical experience.

Authors:  Reut Gurion; Nora G Singer
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592

10.  The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.

Authors:  H M Walters; N Pan; T J A Lehman; A Adams; G D Kalliolias; Y S Zhu; F Santiago; J Nguyen; L Sitaras; S Cunningham-Rundles; T J Walsh; S S Toussi
Journal:  Clin Exp Immunol       Date:  2016-04-13       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.